Date: Thu, 09 Apr 98 21:14:45 EST From: "Snn" <snn@everycom.com> To: Multiple.Recipients.of.List.SNN Subject: StockNetworking News # 8 Message-ID: <35F8025B.92C332BC@everycom.com>
next in thread | raw e-mail | index | archive | help
SNN is delivered to our subscribers via an automated list service; subscribing or unsubscribing instructions are at the end of this letter. September 16, 1998 StockNetworking News No. 8 (SNN) Table of Contents - SNN 8 1. SNN Interviews NuOncology Management 2. Market Commentary 3. SNN in Europe 4. Departments 1. SNN Interviews NuOncology Management NuOncology Labs Inc. Symbol: NLAB - OTC Bulletin Board We apologize for not getting this letter out over the weekend but there is a lot going on with this company - for instance, only today SNN received a request to be kept updated about NuLab's progress, from an Asian based pharmaceutical concern. SNN met with the Senior Management of NuOncology Labs Inc. (NuLabs) on September 10, 1998, at the offices of their investment relations firm, Investor Communication Company (ICC), in Washington, D.C. SNN met with Mr. Robert S. Thomas, Chairman and President, Mr. Philip F. Enlow, Executive Vice President and Mr. Joe Kane a financial consultant to NuOncology Labs Inc. As you can appreciate in a meeting such as this, there are legal and regulatory restrictions on what information can be shared with SNN and our readers, but from the information we did receive there is no doubt this company is making significant progress. We received confirmation that the doctors at the Baker-Sanger Laboratory in Houston, Texas are in the final phases of testing and validating Arglabin and determining its method of action. We also learned that one of the original doctors from Kazakstan is in Houston and assisting in this process. The completion of these tests will be followed by the publishing of a paper, in a recognized medical journal, discussing the findings of NuLab's research team. This paper will be co-authored by at least four physicians with extensive experience and credentials in oncological research, including Dr. R. Michael Williams, NuLab's Medical Director and Chief Scientific Officer. Our impression was that this paper would be completed very soon and if the demeanor of the people we met with is any indication, the results are what NuLab and their shareholders want to see - our feeling is that Arglabin is an FTI. SNN will immediately publish a synopsis of the paper when it is available. We also gained an appreciation of how far ahead of other biopharmaceutical companies NuOncology is at the present time. To the best of SNN's knowledge no one has published information on clinical (human) trials of FTI's. NuLab, on the other hand, has all of the clinical results from the Institute of Phytochemistry, in Kazakstan, for the treatment of over 200 patients with various types of cancers. In addition, on a visit to take place between October 19-29, 1998, further results will be available from clinical trials involving 40 liver cancer and 60 breast cancer patients. These tests have been conducted so as to conform to the international protocols for medical research and should help to add credence to the effectiveness of Arglabin. For this reason alone, NuLabs could be 1-2 years ahead of their many industry competitors who are trying to develop FTI's. (There are at least 8 major pharmaceutical companies conducting research in this area.) We were also pleased to confirm that the patents for the lead compound, Arglabin, and the broader patents for its related and derivative compounds are held in the United States and controlled by NuOncology Labs Inc. One of the key questions to our readers is "What is all this worth?" The best answer SNN could come up with was by making an analogy to another cancer treatment, Taxol, that seems to work in a similar way to Arglabin. Taxol is a $1 billion a year drug today. It has one serious problem in that it is highly toxic. Arglabin, conversely, has minimal toxic side effects and in clinical trials appears to work as well and in some cases better than Taxol, depending on the type of cancer being treated. Assuming that the clinical trials continue to confirm Arglabin's efficacy as a cancer treatment, one way of looking at the valuation of Arglabin would be as a less toxic Taxol. This could easily lead to Arglabin becoming the treatment of choice and thereby giving it a value at least equal to Taxol. In our next letter we will discuss a number of other developments underway in the predictive and chemosensitivity testing areas of NuOncology's business. SNN wishes to thank the management of NuOncology Labs Inc. for taking the time for this meeting and providing ourselves and our readers with these insights into their company and their business. SNN continues to feel very bullish about this company and encourage our readers to closely follow this rapidly developing situation. We believe the shares of NuOncology Labs Inc. (NLAB) to be very attractive at prices up to $10. 2. Market Commentary If the market rally can be credited to the strong hints of an interest rate cut late last week and yesterday, and the slide in the market in the middle of last week can be blamed on Mr. Clinton's personal problems then this market is not in bad shape and is likely to move higher. We believe that Mr. Greenspan's guidance of the economy is key to how the U.S. economic future will unfold. In fact, the future of a number of large Asian and South American economies are dependent on his guidance. The "doom and gloom" crowd project the present set of trends and parameters into the future and get a self fulfilling prophecy of economic disaster. This is where we differ from those that are predicting a more negative outlook - we do not assume the monetary authorities of the major economic powers are going to do nothing. SNN believes that the position that is now being taken by the Fed in the U.S. is that America will have to try and ward off a global recession by initially lowering interest rates and thereby encouraging domestic growth. They will also lend enough money, through the IMF, to reflate many of the world's troubled economies. This scenario is only possible because the US economy is strong, unemployment is low, interest rates are at historic lows (and probably heading lower), there is no apparent inflationary pressures, and there is no external threat to the U.S.. Mr. Clinton is less than 2 months away from what most pundits will soon be referring to as the "lame duck" period of his Presidency. Although we do not think it likely that he will be impeached, if it does occur, we do not think it will be a factor in the economic equation. The bottom line is that the U.S. will need to be the engine to keep many of the world's economies afloat and resuming the type of growth they have shown in the past. For this reason SNN believes that the future for the U.S. economy and stock market is positive and there will continue to be opportunities to profit for the savvy investor. 3. SNN in Europe SNN is expanding its readership in certain 'key' economic centers in Europe. For the convenience of our readers, SNN will now be available in German. For those subscribers who would like to receive their issues of SNN in German simply type "German" in the subject and send an e-mail to : <a href="mailto:wertpapiere@everycom.com">wertpapiere@everycom.com</a> There is no need to write a letter as you will automatically be sent future issues of SNN in German. 4. Departments A. Stock Quotes B. Your Comments are Welcome C. SNN Privacy Policy D. Disclaimer E. How to Subscribe/Unsubscribe A. Stock Quotes To get a stock quote please go to: <a href="http://quote.yahoo.com">http://quote.yahoo.com</a>; B. Your Comments are Welcome If you wish to make a suggestion or comment about SNN please forward it to: <a href="mailto:snncomments@everycom.com">snncomments@everycom.com</a> C. SNN Privacy Policy At SNN we respect your privacy and will NEVER release your e-mail address to a third party for any reason. D. Disclaimer Please read our disclaimer at: <a href="http://www.subscribersite.com/disclaimer.html">http://www.subscribersite.com/disclaimer.html</a>; E. How to Subscribe or Unsubscribe to SNN Please note SNN is delivered to our subscribers by an automated system that ONLY responds to e-mails sent to the following: To subscribe to SNN, send an e-mail to : <a href="mailto:subscribesnn@everycom.com">subscribesnn@everycom.com</a> To unsubscribe to SNN, send an e-mail to : <a href="mailto:unsubscribesnn@everycom.com>unsubscribesnn@everycom.com</a> The above addresses are for subscription commands ONLY and an automatic verification response will be sent. PLEASE NOTE : Please make certain that the address you wish to subscribe or unsubscribe is reflected accurately in the from-field of your e-mail. You can not unsubscribe "jack@any.com" by sending an e-mail from "jack@mail.any.com". If you experience any problems, please send an e-mail to: <a href="mailto:postmaster@everycom.com">postmaster@everycom.com</a> and describe your problem. It will be resolved immediately. SNN # 8 copyright 1998 SNN To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-doc" in the body of the message
Want to link to this message? Use this URL: <https://mail-archive.FreeBSD.org/cgi/mid.cgi?35F8025B.92C332BC>